Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
145
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

348
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
348
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

119
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
119

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Improving the culture surrounding tracheal aspirates in mechanically ventilated children.

Journal of clinical microbiology·2026
Same author

A prognostic human brain network for diffuse midline glioma.

Nature·2026
Same author

Early Neurodevelopmental Outcomes in Children With Congenital Heart Disease.

JAMA network open·2026
Same author

Acute Intensification May Reduce Persistent Coronary Artery Damage from Kawasaki Disease in Infants Younger Than 6 Months.

The Journal of pediatrics·2026
Same author

<i>hTERT</i> Expression, Regulation, and Prognostic Significance in Pediatric Medulloblastoma.

bioRxiv : the preprint server for biology·2026
Same author

Children Hospitalized With Pneumonia Who Complete Oral Antibiotic Treatment Without Complications.

Hospital pediatrics·2026

相关实验视频

Updated: Jul 3, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K

减少C. difficile感染的多模式干预和便检测

Jillian M Cotter1,2, Claire L Stokes1,2, Suhong Tong1

  • 1Department of Pediatrics, University of Colorado, Aurora, Colorado.

Pediatrics
|February 14, 2024
PubMed
概括

实施诊断管理和临床途径显著减少了医院发作的Clostridioides difficile感染 (HO-CDI) 和便检测. 这项质量改善计划还降低了C. difficile检测率和相关成本.

更多相关视频

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.8K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

相关实验视频

Last Updated: Jul 3, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.8K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

科学领域:

  • 传染性疾病 传染性疾病
  • 改善医疗保健质量 改善医疗保健质量
  • 临床微生物学 临床微生物学

背景情况:

  • 多重胃肠道面板增加了Clostridioides difficile (C. difficile) 的检测和便测试的利用率.
  • 在医院发病的C. difficile感染 (HO-CDI) 和不必要的测试构成了挑战.

研究的目的:

  • 将HO-CDI降低20%的目标
  • 将C. difficile的检测率降低20%
  • 在一年内将整体便检测降低20%.

主要方法:

  • 从2018年到2020年进行了一项质量改进项目.
  • 干预措施包括C. difficile测试/治疗途径,修改胃肠道面板选项和临床决策支持工具.
  • 每月使用统计过程控制图表监测结果 (HO-CDI,C. difficile检测,便检测).

主要成果:

  • HO-CDI下降了55% (11到5每10,000个患者日).
  • 难以检测的C.难以检测减少了44% (每10,000个患者日中的18到10).
  • 总体而言,便测试的利用率下降了29% (每10,000个患者日99到70),每年节省了55,649美元.

结论:

  • 诊断管理策略有效地减少了C. difficile感染.
  • 基于证据的临床护理途径改善了测试利用率.
  • 这些综合方法提高了患者护理,降低了医疗保健成本.